Alzheimers Disease - Pipeline Review, H2 2019

Alzheimers Disease - Pipeline Review, H2 2019

Summary

latest Pharmaceutical and Healthcare disease pipeline guide Alzheimers Disease - Pipeline Review, H2 2019, provides an overview of the Alzheimers Disease (Central Nervous System) pipeline landscape.

Alzheimers disease is a progressive, degenerative condition causing damage to the memory and behavior due to the attack on the neurons. These neurons are responsible for the synthesis of neurotransmitter acetylcholine which is further responsible for the transmission of signals. Predisposing factors include age, heredity, cardiovascular diseases or diabetes and environmental factors. Symptoms include depression, anxiety, social withdrawal, irritability and aggressiveness.

Report Highlights

Pharmaceutical and Healthcare latest pipeline guide Alzheimers Disease - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Alzheimers Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alzheimers Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Alzheimers Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 22, 59, 67, 4, 314, 121 and 9 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 3, 100 and 47 molecules, respectively.

Alzheimers Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Alzheimers Disease (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Alzheimers Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Alzheimers Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Alzheimers Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Alzheimers Disease (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Alzheimers Disease (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Alzheimers Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Introduction
Alzheimers Disease - Overview
Alzheimers Disease - Therapeutics Development
Alzheimers Disease - Therapeutics Assessment
Alzheimers Disease - Companies Involved in Therapeutics Development
Alzheimers Disease - Drug Profiles
Alzheimers Disease - Dormant Projects
Alzheimers Disease - Discontinued Products
Alzheimers Disease - Product Development Milestones
Appendix

List Of Tables


Number of Products under Development for Alzheimers Disease, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Alzheimers Disease - Pipeline by 1st Bio Therapeutics Inc, H2 2019
Alzheimers Disease - Pipeline by 2A Pharma AB, H2 2019
Alzheimers Disease - Pipeline by 4D Pharma Plc, H2 2019
Alzheimers Disease - Pipeline by 4P-Pharma SAS, H2 2019
Alzheimers Disease - Pipeline by AB Science SA, H2 2019
Alzheimers Disease - Pipeline by Abaxy Sprl, H2 2019
Alzheimers Disease - Pipeline by AbbVie Inc, H2 2019
Alzheimers Disease - Pipeline by AC Immune SA, H2 2019
Alzheimers Disease - Pipeline by Acelerox LLC, H2 2019
Alzheimers Disease - Pipeline by Acelot Inc, H2 2019
Alzheimers Disease - Pipeline by Actinogen Medical Ltd, H2 2019
Alzheimers Disease - Pipeline by Acumen Pharmaceuticals Inc, H2 2019
Alzheimers Disease - Pipeline by AcuraStem Inc, H2 2019
Alzheimers Disease - Pipeline by Addex Therapeutics Ltd, H2 2019
Alzheimers Disease - Pipeline by ADRx Inc, H2 2019
Alzheimers Disease - Pipeline by Aerobyx LLC, H2 2019
Alzheimers Disease - Pipeline by AfaSci Inc, H2 2019
Alzheimers Disease - Pipeline by Affichem SA, H2 2019
Alzheimers Disease - Pipeline by AFFiRiS AG, H2 2019
Alzheimers Disease - Pipeline by Aibios Co Ltd, H2 2019
Alzheimers Disease - Pipeline by Alector Inc, H2 2019
Alzheimers Disease - Pipeline by AlfaSigma SpA, H2 2019
Alzheimers Disease - Pipeline by Alion Pharmaceuticals Inc, H2 2019
Alzheimers Disease - Pipeline by Alkahest Inc, H2 2019
Alzheimers Disease - Pipeline by Alkermes Plc, H2 2019
Alzheimers Disease - Pipeline by Allgenesis Biotherapeutics Inc, H2 2019
Alzheimers Disease - Pipeline by ALS Biopharma LLC, H2 2019
Alzheimers Disease - Pipeline by Alsonex Pty Ltd, H2 2019
Alzheimers Disease - Pipeline by ALSP Inc, H2 2019
Alzheimers Disease - Pipeline by Alzamend Neuro Inc, H2 2019
Alzheimers Disease - Pipeline by AlzeCure Pharma AB, H2 2019
Alzheimers Disease - Pipeline by Alzheon Inc, H2 2019
Alzheimers Disease - Pipeline by Alzhyme Pty Ltd, H2 2019
Alzheimers Disease - Pipeline by Alzinova AB, H2 2019
Alzheimers Disease - Pipeline by AlzProtect SAS, H2 2019
Alzheimers Disease - Pipeline by Alzyn LLC, H2 2019
Alzheimers Disease - Pipeline by Amarantus Bioscience Holdings Inc, H2 2019
Alzheimers Disease - Pipeline by Amylon LLC, H2 2019
Alzheimers Disease - Pipeline by Amylyx Pharmaceutical Corp, H2 2019
Alzheimers Disease - Pipeline by Anavex Life Sciences Corp, H2 2019

List Of Figures


Number of Products under Development for Alzheimers Disease, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019

Alzheimers Disease - Pipeline Review, H2 2019

Alzheimers Disease - Pipeline Review, H2 2019latest Pharmaceutical and Healthcare disease pipeline guide Alzheimers Disease - Pipeline Review, H2 2019, provides an overview of the Alzheimers Disease (Central Nervous System)

USD 2500 View Report

Alzheimers therapeutics market Alzheimer’s Therapeutics Market By Molecule Type (Cholinesterase Inhibitors, NMDA Receptor Antagonists, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and E Pharmacies), By Region (North America, Europe, Asia Pacific, and Rest of the World) – Global Forecast up to 2025

Global Alzheimers Therapeutics Market Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025[75 pages report] This market research report includes a detailed segmentation of the global Alzheimers Therapeutics market

USD 2750 View Report

Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H2 2019

Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H2 2019latest Pharmaceutical and Healthcare disease pipeline guide Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H2 2019, provides an overview of

USD 2000 View Report

Wilson Disease - Pipeline Review, H2 2019

Wilson Disease - Pipeline Review, H2 2019latest Pharmaceutical and Healthcare disease pipeline guide Wilson Disease - Pipeline Review, H2 2019, provides an overview of the Wilson Disease (Genetic Disorders) pipeline

USD 2000 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available